FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Brainstorm Cell Therapeutics Inc. Stock AnalysisComprehensive stock analysis for Brainstorm Cell Therapeutics Inc. (BCLI) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBCLI
BCLI
Brainstorm Cell Therapeutics Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
BCLI
Home🔹Stocks🔹Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc.

BCLI•NASDAQ

Brainstorm Cell Therapeutics Inc.

BCLI•NASDAQ
Market cap
$6.84M
Sentiment

Your view on BCLI

Mkt Cap
$6.84M
Sentiment
Your view
BCLI
Brainstorm Cell Therapeutics Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
BCLI
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Brainstorm Cell Therapeutics Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Chaim Lebovits
Headquarters
1325 Avenue of Americas, New York City, NY, US
Industry
Biotechnology
Sector
Healthcare
CEO
Chaim Lebovits
Headquarters
1325 Avenue of Americas, New York City, NY, US
Description

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News